GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Intrinsic Value: Projected FCF

Biotech Acquisition Co (Biotech Acquisition Co) Intrinsic Value: Projected FCF : $0.00 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-24), Biotech Acquisition Co's Intrinsic Value: Projected FCF is $0.00. The stock price of Biotech Acquisition Co is $10.15. Therefore, Biotech Acquisition Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Biotech Acquisition Co's Intrinsic Value: Projected FCF or its related term are showing as below:

BIOT's Price-to-Projected-FCF is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.96
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Biotech Acquisition Co Intrinsic Value: Projected FCF Historical Data

The historical data trend for Biotech Acquisition Co's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co Intrinsic Value: Projected FCF Chart

Biotech Acquisition Co Annual Data
Trend Dec20 Dec21
Intrinsic Value: Projected FCF
- -

Biotech Acquisition Co Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Biotech Acquisition Co's Intrinsic Value: Projected FCF

For the Shell Companies subindustry, Biotech Acquisition Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotech Acquisition Co's Price-to-Projected-FCF Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Biotech Acquisition Co's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Biotech Acquisition Co's Price-to-Projected-FCF falls into.



Biotech Acquisition Co Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Biotech Acquisition Co  (NAS:BIOT) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Biotech Acquisition Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=10.15/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotech Acquisition Co Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Biotech Acquisition Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Traded in Other Exchanges
N/A
Address
545 West 25th Street, 20th Floor, New York, NY, USA, 10001
Website
Biotech Acquisition Co is a blank check company.
Executives
Albert F Hummel director, officer: Chief Investment Officer PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc 10 percent owner 545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari director 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry officer: Chief Operating Officer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer director, 10 percent owner, officer: Chief Executive Officer 545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci officer: CFO & Treasurer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001

Biotech Acquisition Co (Biotech Acquisition Co) Headlines

From GuruFocus